Log In
Print
BCIQ
Print
Print this Print this
 

Oral Relistor, methylnaltrexone (MOA-728)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionPeripheral mu opioid receptor (MOR; OPRM1) antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC); Treat opioid-induced constipation (OIC) in non-cancer patients with chronic pain
Regulatory Designation
Partner Lupin Ltd.; Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$15,624.0M

$14,789.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today